Core Viewpoint - Trinity Biotech plc has provided an update on its trading activities for Q4 2025, highlighting both challenges and strategic advancements in its business operations, particularly in the areas of HIV testing and diabetes management solutions [1]. Trading Update - The company expects Q4 2025 revenue to be between approximately $11.5 million and $12.5 million, a decrease from $15.9 million in Q4 2024, primarily due to disruptions in the global health market for HIV testing and adjustments in manufacturing processes [8]. Business Update - The company is focused on profitable growth and advancing its innovation agenda, including the flagship development of CGM+ [3]. - Key regulatory approvals have been secured, including the outsourcing of production for the Uni-Gold™ HIV rapid test, which is a priority in the Comprehensive Transformation Plan [4]. - The company is experiencing strong demand for its Uni-Gold™ HIV test and expects this segment to contribute significantly to revenue in 2026 [5]. - The transition to outsourced manufacturing aims to reduce fixed costs and mitigate revenue variability, although it may introduce temporary fluctuations in quarterly revenue [6]. - The company is enhancing its diabetes care solutions, having received a Gold Classification from the IFCC for its Premier Hb9210 HbA1c monitoring solution and is expanding its commercial efforts in the US and Brazil [7][10]. Pipeline Developments - The company continues to advance key strategic growth projects, including the development of CGM+, EpiCapture for prostate cancer monitoring, and PrePsia for early pregnancy screening [13].

Financial Performance - Revenue for Q3 2025 was $14.3 million, compared to $15.2 million in Q3 2024[7] - Like-for-like revenue (excluding discontinued product lines) was $14.2 million in Q3 2025, compared to $14.6 million in Q3 2024[4, 7] - Gross profit increased to $6.5 million in Q3 2025 from $5.3 million in Q3 2024, with gross margin improving to 45.2% from 35.0%[7] - The company achieved positive Adjusted EBITDA of $0.5 million for the quarter, compared to negative $1.4 million in Q3 2024[4] - Net loss was $5.1 million in Q3 2025, compared to $4.8 million in Q3 2024[4] - Basic and diluted loss per ADS was $0.28 in Q3 2025, compared to $0.46 in Q3 2024[4] Key Revenue Drivers - TrinScreen HIV sales were $1.0 million in Q3 2025, compared to $2.4 million in Q3 2024, reflecting the resumption of manufacture[7] - UniGold HIV sales showed strong performance with sales of $2.6 million in Q3 2025, compared to $1.6 million in Q3 2024[7] - Haemoglobin revenue increased to $5.7 million in Q3 2025 from $5.1 million in Q3 2024[7] Expenses and Liquidity - R&D expense was $0.8 million in Q3 2025, compared to $1.0 million in Q3 2024[10] - SG&A expense decreased to $6.2 million in Q3 2025 from $6.5 million in Q3 2024[10] - Cash balance at the end of Q3 2025 was $1.3 million, compared to $2.8 million in Q3 2024[10]

Core Insights - Trinity Biotech has received a significant order for 9 million units of its TrinScreen HIV screening product, indicating a recovery in the global HIV testing market [1][2][4] - The company achieved positive Adjusted EBITDA in Q3 2025 and anticipates further profitability growth in Q1 and Q2 2026 through its Comprehensive Transformation Plan [1][8][10] TrinScreen HIV Order - The order reflects renewed commitment from global health organizations to support HIV screening, particularly in heavily affected regions [2] - TrinScreen HIV is a WHO-prequalified rapid diagnostic test designed for high-volume screening, providing reliable results in various clinical settings [2] Manufacturing and Supply Chain - Trinity Biotech will produce the tests through a WHO-approved outsourced manufacturing process, allowing for efficient scalability [3] - The company expects to fulfill the order in Q4 2025 and Q1 2026, adjusting its manufacturing and supply chain to meet increased demand [3] Financial Performance - Revenues for Q3 2025 increased by 32% to $14.3 million compared to $10.8 million in Q2 2025, driven by a $2.1 million increase in rapid HIV test sales and a rise in haemoglobin product sales [8] - Gross profit for Q3 2025 was $6.5 million, with an increase in gross margin from 42.6% to 45.2% due to operational changes [8] - Adjusted EBITDA for Q3 2025 was $0.5 million, a significant improvement from negative $2.1 million in Q2 2025 [8] Strategic Positioning - The order is expected to positively impact revenue and profitability, highlighting the company's strategic position in the global infectious disease diagnostics market [4] - The company is focused on immediate growth opportunities and expanding into international markets with new product offerings [7][14] Management Transition - Susan O'Connor has completed her term as interim Chief Financial Officer, with Paul Murphy promoted to the role [10]

Core Insights - Trinity Biotech plc reported a total revenue of $15.9 million for Q4 2024, representing an 18.1% increase from $13.4 million in Q4 2023, driven primarily by a significant growth in Point-of-Care revenues [3][10] - The company is undergoing a Comprehensive Transformation Plan aimed at improving profitability, which includes consolidating manufacturing operations and enhancing offshore production capabilities [5][15] - Despite revenue growth, the company reported a net loss of $17.0 million for Q4 2024, an increase from $5.5 million in Q4 2023, largely due to restructuring costs and increased operational expenses [7][12] Financial Performance - Q4 2024 total revenues were $15.9 million, up from $13.4 million in Q4 2023, with Point-of-Care revenues increasing by 158.0% to $5.5 million [3][10] - Clinical laboratory revenues decreased by 8.6% to $10.3 million, attributed to a 34.3% decline in Infectious Diseases revenues [4][10] - For the fiscal year 2024, total revenues were $61.6 million, an 8.3% increase from $56.8 million in 2023, with Point-of-Care revenues growing by 91.8% [10][11] Profitability and Losses - Gross profit for Q4 2024 was $4.9 million, with a gross margin of 30.8%, down from 34.0% in Q4 2023 [6][10] - The net loss for the fiscal year 2024 was $31.8 million, compared to a loss of $24.0 million in 2023, influenced by restructuring costs and a decrease in impairment charges [12][13] - Selling, general, and administrative expenses decreased by $2.3 million to $28.8 million in 2024, reflecting cost-cutting measures [13] Cash Flow and Liquidity - The cash balance increased to $5.2 million at the end of Q4 2024 from $3.7 million at the end of Q4 2023, with cash generated from operating activities rising to $3.6 million [8][10] - The company entered into an amended credit agreement with Perceptive Advisors, providing an additional liquidity of approximately $4.5 million [15][16] Strategic Initiatives - The company has made significant progress in consolidating its manufacturing operations, including the transfer of production processes to other sites and the reduction of headcount at its Kansas facility [5] - Trinity Biotech is advancing the development of its next-generation continuous glucose monitoring (CGM) solution, with recent pre-pivotal testing completed [5][10]